TAM
NWBO

Telluride Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Telluride Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$183K Buy
+27,238
New +$173K 0.16% 208

Other funds holding NWBO

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Telluride Asset Management's NWBO Position: Q2 2014 in Review

Telluride Asset Management opened a new position in Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2014: 27,238 shares worth $183K. The stake represents 0.16% of the portfolio and ranks #208 among its holdings.

80 funds tracked by Wall St. Rank hold NWBO as of Q2 2014.

  • Telluride Asset Management held 27,238 shares of Northwest Biotherapeutics, Inc. Common stock worth $183K as of Q2 2014.
  • Northwest Biotherapeutics, Inc. Common stock was a new Telluride Asset Management position in Q2 2014.
  • Northwest Biotherapeutics, Inc. Common stock made up 0.16% of Telluride Asset Management's portfolio in Q2 2014, its #208 holding.
  • 80 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2014.

Based on Telluride Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.